Mn Services Vermogensbeheer B.V. Reduces Stock Position in Gilead Sciences, Inc. (NASDAQ:GILD)

Mn Services Vermogensbeheer B.V. lowered its stake in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 2.4% during the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 480,855 shares of the biopharmaceutical company’s stock after selling 11,900 shares during the period. Mn Services Vermogensbeheer B.V.’s holdings in Gilead Sciences were worth $40,315,000 at the end of the most recent reporting period.

Several other institutional investors have also recently made changes to their positions in the stock. PDS Planning Inc lifted its position in shares of Gilead Sciences by 10.6% during the third quarter. PDS Planning Inc now owns 4,500 shares of the biopharmaceutical company’s stock worth $377,000 after acquiring an additional 433 shares in the last quarter. Asset Management One Co. Ltd. increased its holdings in shares of Gilead Sciences by 1.8% in the third quarter. Asset Management One Co. Ltd. now owns 664,864 shares of the biopharmaceutical company’s stock worth $55,742,000 after purchasing an additional 12,017 shares during the period. National Pension Service increased its holdings in shares of Gilead Sciences by 13.3% in the third quarter. National Pension Service now owns 2,807,643 shares of the biopharmaceutical company’s stock worth $235,393,000 after purchasing an additional 330,290 shares during the period. Cohen Capital Management Inc. bought a new position in shares of Gilead Sciences in the third quarter worth $200,000. Finally, Old North State Wealth Management LLC increased its holdings in shares of Gilead Sciences by 2.7% in the third quarter. Old North State Wealth Management LLC now owns 57,889 shares of the biopharmaceutical company’s stock worth $4,857,000 after purchasing an additional 1,498 shares during the period. Hedge funds and other institutional investors own 83.67% of the company’s stock.

Insiders Place Their Bets

In other Gilead Sciences news, insider Merdad Parsey sold 2,000 shares of the business’s stock in a transaction on Tuesday, October 1st. The shares were sold at an average price of $83.83, for a total value of $167,660.00. Following the sale, the insider now owns 100,189 shares in the company, valued at $8,398,843.87. The trade was a 0.00 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. In other Gilead Sciences news, insider Merdad Parsey sold 2,000 shares of the business’s stock in a transaction on Tuesday, October 1st. The shares were sold at an average price of $83.83, for a total value of $167,660.00. Following the sale, the insider now owns 100,189 shares in the company, valued at $8,398,843.87. The trade was a 0.00 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Johanna Mercier sold 29,357 shares of the business’s stock in a transaction on Thursday, September 12th. The stock was sold at an average price of $83.78, for a total transaction of $2,459,529.46. Following the completion of the sale, the insider now owns 78,127 shares in the company, valued at approximately $6,545,480.06. The trade was a 0.00 % decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders sold 36,847 shares of company stock valued at $3,033,340. Company insiders own 0.16% of the company’s stock.

Gilead Sciences Stock Up 0.6 %

Shares of GILD traded up $0.58 on Monday, hitting $90.09. 1,690,158 shares of the stock traded hands, compared to its average volume of 6,997,873. The company has a debt-to-equity ratio of 1.18, a quick ratio of 0.95 and a current ratio of 1.14. Gilead Sciences, Inc. has a one year low of $62.07 and a one year high of $90.71. The company has a market capitalization of $112.16 billion, a PE ratio of 109.16, a P/E/G ratio of 3.09 and a beta of 0.17. The business has a 50 day simple moving average of $83.79 and a 200 day simple moving average of $74.21.

Gilead Sciences (NASDAQ:GILD) last posted its earnings results on Thursday, August 8th. The biopharmaceutical company reported $2.01 EPS for the quarter, topping analysts’ consensus estimates of $1.61 by $0.40. Gilead Sciences had a net margin of 3.79% and a return on equity of 29.34%. The business had revenue of $6.95 billion during the quarter, compared to the consensus estimate of $6.64 billion. As a group, equities analysts forecast that Gilead Sciences, Inc. will post 3.75 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several research analysts have recently weighed in on GILD shares. Sanford C. Bernstein started coverage on shares of Gilead Sciences in a report on Thursday, October 17th. They issued an “outperform” rating and a $105.00 price target on the stock. Wells Fargo & Company raised shares of Gilead Sciences from an “equal weight” rating to an “overweight” rating and upped their price target for the stock from $78.00 to $100.00 in a report on Monday, October 7th. Evercore ISI raised Gilead Sciences to a “strong-buy” rating in a research note on Friday, August 9th. BMO Capital Markets increased their target price on Gilead Sciences from $85.00 to $94.00 and gave the company an “outperform” rating in a research note on Thursday, October 17th. Finally, Royal Bank of Canada reissued a “sector perform” rating and issued a $75.00 target price on shares of Gilead Sciences in a research note on Tuesday, October 29th. Ten equities research analysts have rated the stock with a hold rating, eleven have given a buy rating and three have assigned a strong buy rating to the company’s stock. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average price target of $86.85.

Gilead Sciences Company Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.